SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as community members discuss Elon Musk's recent $1 billion stock purchase and its potential impact. Some believe this signals confidence and a potential squeeze, while others express skepticism, citing concerns about valuation and past performance. The stock's movement is also being tied to broader market factors like potential Fed rate cuts and the company's future prospects in AI and robotics.

Slopana

Slopana is trending as community members rally around the Solana-based meme coin, referring to it as digital slop and Solana's mascot. Conversations highlight the strong community, a doxxed CTO, and the coin's availability on Phantom Wallet. Many believe Slopana has the potential for significant growth within the Solana ecosystem, with some drawing parallels to other successful meme coins.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid growing interest in AI-driven security solutions and biometric software deployments, particularly following news of a congresswoman purchasing shares. The community is actively discussing potential government contracts, short squeeze opportunities, and comparisons to $PLTR, with bullish investors pointing to favorable chart setups and anticipating significant gains. Sentiment suggests building confidence in BBAI's long-term potential within the AI and defense sectors.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market reaches new all-time highs, fueling discussions about a potential rate cut and its implications. Community members are actively debating whether the expected rate cut is already priced in and if a "sell the news" event is on the horizon. Some traders express concerns about overbought conditions and the potential for a significant pullback, while others remain bullish, citing positive economic data and ongoing momentum.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its potential for a significant move, fueled by its enhanced anticoagulation pipeline. Community members are closely watching for a breakout above resistance, anticipating a bullish run if volume increases. Recent news highlights the company's pipeline expansion and portfolio acquisition, further contributing to the positive sentiment.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

$JINGLE.X is trending as the community discusses potential gains, with many expressing excitement about its potential. Recent price dips are seen as buying opportunities by some, while others suggest that $JINGLE.X may benefit from the success of other meme coins.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo ($OKLO) is trending as investors discuss its potential to power AI data centers and a recently announced fuel recycling facility, with the stock reaching new all-time highs. Community members debate the company's valuation given its pre-revenue status, while some compare it to peers in the nuclear energy sector and highlight potential upside based on technical analysis.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending due to increased investor interest in uranium and rare earth elements, fueled by discussions around government contracts and strategic positioning. Community talking points revolve around whether the stock is currently undervalued or already priced in, with some traders taking profits after recent gains. A U.S. strategic uranium reserve is being considered as a potential catalyst.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

Definitive's EDGE.X is trending as community members discuss its potential for significant gains, drawing comparisons to AERO's early success and highlighting its strong performance amidst broader market fluctuations. Speculation around a potential Binance listing and the project's unique features, like its DEX platform and cross-chain capabilities, are fueling bullish sentiment, with many anticipating a move towards dollar land.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community actively discusses new meme coins launching on the network, particularly those available via Phantom Wallet and Pump.fun. Recent large purchases of SOL by Galaxy Digital have further fueled optimism, with some traders speculating about a potential climb towards a significantly higher price point. Bullish sentiment is building as the community anticipates a potential breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus 

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected first-quarter loss.The clinical-stage immunology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial">reported</a> a net loss of $0.64 per share for the quarter compared to a loss of $0.52 for the corresponding quarter of 2024, and lower than an estimated loss of $0.72 per share, as per Finchat data.The company’s increased research and development expenses, as well as general and administrative expenses, weighed on its bottom line, with the net loss widening to $106.45 million.Immunovant is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.Its candidate IMVT-1402 is being developed for the treatment of multiple illnesses, including Graves’ disease (GD), difficult-to-treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Sjögren’s Disease (SjD).The company ended the quarter with cash and cash equivalents totalling approximately $714 million, expected to provide runway till 2027.Last month, Immunovant announced changes to its leadership as part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.The company appointed Eric Venker as CEO, replacing Pete Salzmann, and Tiago Girao as CFO, replacing Renee Barnett.On Stocktwits, retail sentiment around IMVT stayed within the ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_10_09_02_AM_png_50dfeaa22a.webp" alt="IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> According to data from Koyfin, 12 of the 15 analysts covering Immunovant rate it a ‘Buy’ or higher, while three rate it a ‘Hold’. The stock has an average price target of $45.15, representing an upside of over 200% from its current share price.<a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by about 43% this year and by about 51% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/iridium-partners-with-syniverse-to-launch-global-satellite-service/ch0AYoSRbto">Iridium Partners With Syniverse To Launch Global Satellite Service: Retail Stays Confident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Equity

Immunovant, Inc. (IMVT) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant">announced</a> on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, following Salzmann's retirement from his role.Venker, meanwhile, will continue to serve on Immunovant’s Board of Directors.Tiago Girao will be the company’s new CFO, replacing Renee Barnett. Girao was formerly the CFO of biopharmaceutical company Telavant Holdings.Immunovant stated that these changes are part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.&nbsp; George Migausky has stepped down from the Immunovant board of directors, and Robert Susman and Jacob Bauer have joined the board, effective April 18, 2025, the company added.Immunovant is a clinical-stage immunology company developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.The company now plans to study its IMVT-1402, an anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases, in the treatment of Sjögren’s disease and Cutaneous Lupus Erythematosus as well. No therapies have been explicitly approved for the treatment of Sjögren’s disease to date, it said.The company said it is beginning to conclude development activities for batoclimab, an anti-FcRn monoclonal antibody.Venker said that Immunovant has shown “compelling efficacy data” in clinical trials for batoclimab in Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, and Thyroid Eye Disease.Immunovant said that its current cash balance is expected to provide a runway till 2027.On Stocktwits, retail sentiment around the stock jumped from ‘bearish’ to ‘bullish’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:644/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_8_09_32_AM_png_03ceffe093.webp" alt="IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits" width="644" height="147"><figcaption>IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by over 40% so far this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-as-trump-tariffs-cloud-earnings-season/chQiK8CRbQg">Dow Futures Decline As Trump’s Tariffs Cloud Earnings Season: Tech Bull Says ‘White House Needs Trade Deals Done Quick’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24...

What the Options Market Tells Us About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Immunovant Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$15.53
Prev Close	$16.16
Open	$16.21
Dividend Yield	0.00%
50-Day Moving Average	$16.34
Beta	0.99
Avg. Volume	1.14M
PE Ratio	-5.68

52-Week High	$32.10
52-Week Low	$12.72
Market Capitalization	$2.82B
EPS (Annual)	-$2.73
Price to Book	4.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMVT
Immunovant Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMVT News

IMVT Immunovant Inc